Acute Renal Failure (ARF) represents one of the biggest problems in the pet clinic resulting in a high mortality.
Recent studies have demonstrated the efficacy of MSC in the recovery of kidneys with ARF that presented ischemia-reperfusion injuries.
It has been shown that the use of MSCs in IRA drastically reduces mortality (reducing the mortality to 0% using MSC vs. 47% mortality in patients without MSC).
Moreover it also produces a marked decrease in creatinine serum.
Furthermore, histological studies showed that the patients who had used MSC experienced a marked decrease in tubular necrosis and tissue macrophage infiltration, resulting in a decrease in inflammation.